Update README.md
Browse files
README.md
CHANGED
|
@@ -1,6 +1,6 @@
|
|
| 1 |
# moPPIt: De Novo Generation of Motif-Specific Peptide Binders via Multi-Objective Discrete Flow Matching
|
| 2 |
|
| 3 |
-
<img src="https://cdn-uploads.huggingface.co/production/uploads/649ef40be56dc456b7a36649/2P-06_gxQ_Dv3x-i1aEWH.png" width="
|
| 4 |
|
| 5 |
Targeting specific functional motifs, whether conserved viral epitopes, intrinsically disordered regions (IDRs), or fusion breakpoints, is essential for modulating protein function and protein-protein interactions (PPIs). Current design methods, however, depend on stable tertiary structures, limiting their utility for disordered or dynamic targets. Here, we present a motif-specific PPI targeting algorithm (moPPIt), a framework for the de novo generation of motif-specific peptide binders derived solely from target sequence data. The core of this approach is BindEvaluator, a transformer architecture that interpolates protein language model embeddings to predict peptide-protein binding site interactions with high accuracy (AUC = 0.97). We integrate this predictor into a novel Multi-Objective-Guided Discrete Flow Matching (MOG-DFM) framework, which steers generative trajectories toward peptides that simultaneously maximize binding affinity and motif specificity. After comprehensive in silico validation of binding and motif-specific targeting, we validate moPPIt in vitro by generating binders that strictly discriminate between the FN3 and IgG domains of NCAM1, confirming domain-level specificity, and further demonstrate precise targeting of IDRs by generating binders specific to the N-terminal disordered domain of β-catenin. In functional, disease-relevant assays, moPPIt-designed peptides targeting the GM-CSF receptor effectively block macrophage polarization. Finally, we demonstrate therapeutic utility in cell engineering, where binders directed against the tumor antigen AGR2 drive specific CAR T regulatory cell activation. In total, moPPIt serves as a purely sequence-based paradigm for controllably targeting the "undruggable" and disordered proteome.
|
| 6 |
|
|
|
|
| 1 |
# moPPIt: De Novo Generation of Motif-Specific Peptide Binders via Multi-Objective Discrete Flow Matching
|
| 2 |
|
| 3 |
+
<img src="https://cdn-uploads.huggingface.co/production/uploads/649ef40be56dc456b7a36649/2P-06_gxQ_Dv3x-i1aEWH.png" width="80%">
|
| 4 |
|
| 5 |
Targeting specific functional motifs, whether conserved viral epitopes, intrinsically disordered regions (IDRs), or fusion breakpoints, is essential for modulating protein function and protein-protein interactions (PPIs). Current design methods, however, depend on stable tertiary structures, limiting their utility for disordered or dynamic targets. Here, we present a motif-specific PPI targeting algorithm (moPPIt), a framework for the de novo generation of motif-specific peptide binders derived solely from target sequence data. The core of this approach is BindEvaluator, a transformer architecture that interpolates protein language model embeddings to predict peptide-protein binding site interactions with high accuracy (AUC = 0.97). We integrate this predictor into a novel Multi-Objective-Guided Discrete Flow Matching (MOG-DFM) framework, which steers generative trajectories toward peptides that simultaneously maximize binding affinity and motif specificity. After comprehensive in silico validation of binding and motif-specific targeting, we validate moPPIt in vitro by generating binders that strictly discriminate between the FN3 and IgG domains of NCAM1, confirming domain-level specificity, and further demonstrate precise targeting of IDRs by generating binders specific to the N-terminal disordered domain of β-catenin. In functional, disease-relevant assays, moPPIt-designed peptides targeting the GM-CSF receptor effectively block macrophage polarization. Finally, we demonstrate therapeutic utility in cell engineering, where binders directed against the tumor antigen AGR2 drive specific CAR T regulatory cell activation. In total, moPPIt serves as a purely sequence-based paradigm for controllably targeting the "undruggable" and disordered proteome.
|
| 6 |
|